Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

NCT03122548 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Low enrollment and lack of clinical activity in other CRS-207 studies.

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma

Interventions

BIOLOGICAL: CRS-207
BIOLOGICAL: Pembrolizumab

Sponsor

Aduro Biotech, Inc.

Collaborators

[object Object]